Arcturus Therapeutics

Arcturus Therapeutics San Diego Office Headquarters

Latest Publications

A Single Dose of Self-Transcribing and Replicating RNA Based SARS-CoV-2 Vaccine Produces Protective Adaptive Immunity In Mice
September 2020
A self-transcribing and replicating RNA (STARR) based vaccine (LUNAR® 36 -COV19) has 37 been developed to prevent SARS-CoV-2 infection. The vaccine encodes an alphavirus-based 38 replicon and the SARS-CoV-2 full length spike glycoprotein.
Anti-HFRS Human IgG Produced in Transchromosomic Bovines Has Potent Hantavirus Neutralizing Activity and Is Protective in Animal Models
We explored an emerging technology to produce anti-Hantaan virus (HTNV) and anti-Puumala virus (PUUV) neutralizing antibodies for use as pre- or post-exposure prophylactics.

Publications

Publication
Journal/Date
Title
Overview
Publication
Journal/Date
September 2020
Title
A Single Dose of Self-Transcribing and Replicating RNA Based SARS-CoV-2 Vaccine Produces Protective Adaptive Immunity In Mice
Overview
A self-transcribing and replicating RNA (STARR) based vaccine (LUNAR® 36 -COV19) has 37 been developed to prevent SARS-CoV-2 infection. The vaccine encodes an alphavirus-based 38 replicon and the SARS-CoV-2 full length spike glycoprotein.
Publication
Journal/Date
May 2020
Title
Anti-HFRS Human IgG Produced in Transchromosomic Bovines Has Potent Hantavirus Neutralizing Activity and Is Protective in Animal Models
Overview
We explored an emerging technology to produce anti-Hantaan virus (HTNV) and anti-Puumala virus (PUUV) neutralizing antibodies for use as pre- or post-exposure prophylactics.
Publication
Journal/Date
May 2020
Title
Lipid Nanoparticle Formulation Increases Efficiency of DNA-Vectored Vaccines/Immunoprophylaxis in Animals Including Transchromosomic Bovines
Overview
The use of nucleic acid as a drug substance for vaccines and other gene-based medicines continues to evolve. Here, we have used a technology originally developed for mRNA in vivo delivery to enhance the immunogenicity of DNA vaccines. We demonstrate that neutralizing antibodies produced in rabbits and nonhuman primates injected with lipid nanoparticle (LNP)-formulated Andes virus or Zika virus DNA vaccines are elevated over unformulated vaccine.
Publication
Journal/Date
January 2017
Title
Systemic delivery of factor IX messenger RNA for protein replacement therapy
Overview
Safe and efficient delivery of messenger RNAs for protein replacement therapies offers great promise but remains challenging. In this report, we demonstrate systemic, in vivo, nonviral mRNA delivery through lipid nanoparticles (LNPs) to treat a Factor IX (FIX)-deficient mouse model of hemophilia B.

Posters

Poster
Journal/Date
Title
Overview
Poster
Title
LUNAR-CF a mRNA Replacement Therapy for Cystic Fibrosis
Overview
Arcturus Therapeutics is a nucleic acid medicines company focused on developing RNA therapeutics to treat rare diseases. Our proprietary LUNAR® lipid-mediated delivery technology enables the efficient delivery of any mRNA into a variety of cell types and tissues, and can be optimized for multiple routes of administration.
Poster
Journal/Date
October 2018
Title
LUNAR® selective delivery of nebulized mRNA into murine lung epithelial cells
Overview
LUNAR® lipid nanoparticles carrying the mRNA payload reaches the target cell, where it fuses with the plasma membrane forming an intracellular endosome. This endosomic particle undergoes a pH-mediated disruption that causes the breakdown of the biodegradable nanoparticle and the delivery of the mRNA into the cytoplasm.
Poster
Journal/Date
April 2019
Title
mRNA Therapy For Ornithine Transcarbamylase Deficiency
Overview
LUNAR®-OTC treats patients suffering from ornithine transcarbamylse deficiency (OTCD) using mRNA to replace the wild-type human enzyme. OTCD is a rare metabolic disease in which the urea cycle cannot efficiently convert ammonia into urea. The efficacy of LUNAR®-OTC was evaluated in an animal model of OTCD ameliorating certain OTCD disease phenotypes in mice.